Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)
The ATOMIC Study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic HCV Infection Genotype 1,4, 5, or 6
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00935
- University of Puerto Rico
-
San Juan, Puerto Rico
- Fundacion De Investigacion de Diego
-
-
-
-
Alabama
-
Montgomery, Alabama, United States, 36116
- Alabama Liver and Digestive Specialist
-
-
Arkansas
-
Jonesboro, Arkansas, United States, 72401
- Clopton Clinic
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Research Institute
-
Burbank, California, United States, 91505
- Providence Clinical Research
-
Coronado, California, United States, 92118
- Southern California Liver Centers
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center
-
Oceanside, California, United States, 92056
- eStudy Site
-
San Diego, California, United States, 92114
- Desta Digestive Disease Medical Center
-
San Diego, California, United States, 92123
- Medical Associates Reseach Group
-
San Diego, California, United States, 92154
- Kaiser Permanente Hepatology Research
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver Transplant Center and Hepatology Clinic
-
Englewood, Colorado, United States, 80110
- South Denver Gastreoenterology
-
-
Florida
-
Bradenton, Florida, United States, 34209
- Pointe West Infectious Disease
-
Deland, Florida, United States, 32720
- Avail Clinical Research
-
Gainesville, Florida, United States, 32610
- University of Florida College of Medicine
-
Orlando, Florida, United States, 32803
- Orlando Immunology Center
-
Orlando, Florida, United States, 32806
- Internal Medicine Specialists
-
Trinity, Florida, United States, 34655
- Advanced Research Institute
-
Wellington, Florida, United States, 33414
- South Florida Center of Gastroenterology
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Atlanta Gastroenterology Associates
-
Marietta, Georgia, United States, 30060
- Gastrointestinal Specialists of Georgia
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University Of Chicago Medical Center
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Investigative Clinical Research
-
Reisterstown, Maryland, United States, 21136
- Clinical Associates Research
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deconess Medical Center
-
Worcester, Massachusetts, United States, 01655
- U Mass Memorial Medical Center
-
-
Michigan
-
Novi, Michigan, United States, 48377
- Henry Ford Health System
-
-
Missouri
-
St. Louis, Missouri, United States, 63104
- St. Louis University Gastroenterology and Hepatology Clinical Research
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico Health Science Center
-
-
New York
-
Manhasset, New York, United States, 11303
- North Shore University Hospital
-
New York, New York, United States, 10021
- New York Presbyterian Hospital
-
New York, New York, United States, 10029
- Mt. Sinai Medical Center
-
New York, New York, United States, 10016
- Concorde Medical Group
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Asheville Gastroenterology Associates
-
Durham, North Carolina, United States
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
-
South Carolina
-
Columbia, South Carolina, United States, 29204
- Columbia Gastroenterology Associates
-
-
Texas
-
Arlington, Texas, United States, 76012
- North Texas Research Institute
-
Austin, Texas, United States, 78705
- Central Texas Cinical Research
-
Dallas, Texas, United States, 75246
- Baylor University
-
Houston, Texas, United States, 77030
- Baylor/ St. Luke's Advanced Liver Therapy
-
San Antonio, Texas, United States, 78215
- Alamo Medical Research
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Digestive and Liver Disease Specialist
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females with Chronic Hepatitis C (HCV) Genotype 1,4,5,6, or indeterminate
- Naive to previous HCV treatment
Exclusion Criteria:
- Positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab
- History of any other clinically significant chronic liver disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SOF+PEG+RBV 12 weeks
Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
|
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Other Names:
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Other Names:
Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Other Names:
|
|
Experimental: SOF+PEG+RBV 24 weeks
Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
|
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Other Names:
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Other Names:
Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Other Names:
|
|
Experimental: SOF+PEG+RBV 12 week/Rerandomization Group
Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
|
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Other Names:
Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Other Names:
Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)
Time Frame: Post-treatment Week 24
|
SVR24 was defined as HCV RNA < the limit of detection (LOD; < 15 IU/mL) 24 weeks after the last dose of study drug.
|
Post-treatment Week 24
|
|
Percentage of Participants Who Experienced Adverse Events
Time Frame: Baseline (Day 1) to post-treatment Day 30
|
Adverse events (AEs) occurring from baseline (Day 1 for all groups) to 30 days following the last dose of study drug were summarized across the participant population.
A participant was counted once if they had a qualifying event.
|
Baseline (Day 1) to post-treatment Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)
Time Frame: Post-treatment Week 12
|
SVR12 was defined as HCV RNA < LOD 12 weeks after the last dose of study drug.
|
Post-treatment Week 12
|
|
Change in HCV RNA at Week 2
Time Frame: Baseline (Day 1) to Week 2
|
Baseline (Day 1) to Week 2
|
|
|
Change in HCV RNA at Week 4
Time Frame: Baseline (Day 1) to Week 4
|
Baseline (Day 1) to Week 4
|
|
|
Change in HCV RNA at Week 8
Time Frame: Baseline (Day 1) to Week 8
|
Baseline (Day 1) to Week 8
|
|
|
Change in HCV RNA at Week 12
Time Frame: Baseline (Day 1) to Week 12
|
Baseline (Day 1) to Week 12
|
|
|
Percentage of Participants With HCV RNA < LOD at Week 2
Time Frame: Week 2
|
Week 2
|
|
|
Percentage of Participants With HCV RNA Below < LOD at Week 4
Time Frame: Week 4
|
Week 4
|
|
|
Percentage of Participants With HCV RNA Below < LOD at Week 8
Time Frame: Week 8
|
Week 8
|
|
|
Percentage of Participants With HCV RNA Below < LOD at Week 12
Time Frame: Week 12
|
Week 12
|
|
|
Percentage of Participants With HCV RNA Below < LOD at Week 24
Time Frame: Week 24
|
Week 24
|
|
|
Percentage of Participants With ALT Normalization at Week 12
Time Frame: Baseline (Day 1) to Week 12
|
ALT normalization was defined as ALT > ULN at baseline and ALT ≤ ULN at Week 12.
|
Baseline (Day 1) to Week 12
|
|
Percentage of Participants With ALT Normalization at Week 24
Time Frame: Baseline (Day 1) to Week 24
|
ALT normalization was defined as ALT > ULN at baseline (Day 1 for all groups) and ALT ≤ ULN at Week 24.
|
Baseline (Day 1) to Week 24
|
|
Percentage of Participants With ALT Normalization at Post-treatment Week 4
Time Frame: Baseline (Day 1) to Post-treatment Week 4
|
ALT normalization was defined as ALT > ULN at baseline (Day 1 for all groups) and ALT ≤ ULN at Post-treatment Week 4.
|
Baseline (Day 1) to Post-treatment Week 4
|
|
Percentage of Participants With Virologic Failure During Treatment
Time Frame: Baseline (Day 1) to Week 24
|
Virologic failure was defined as either
Baseline was Day 1 for all groups. |
Baseline (Day 1) to Week 24
|
|
Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).
Time Frame: End of treatment to Post-treatment Week 24
|
Viral relapse was defined as HCV RNA < 15 IU/mL at end of treatment, confirmed with 2 consecutive values or last available measurement.
|
End of treatment to Post-treatment Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5. Erratum In: Lancet. 2014 Mar 8;383(9920):870.
- Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15;381(9883):2100-7. doi: 10.1016/S0140-6736(13)60247-0. Epub 2013 Mar 15.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
Other Study ID Numbers
Other Study ID Numbers
- P7977-0724
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.